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n melanocytes and melanoma cells 
 
 
 
-melanocyte stimu-
lating hormone (
 
 
 
-MSH), via the cAMP pathway, elicits
a large array of biological responses that control me-
lanocyte differentiation and inﬂuence melanoma develop-
ment or susceptibility. In this work, we show that cAMP
transcriptionally activates 
 
Hif1a
 
 gene in a melanocyte
cell–speciﬁc manner and increases the expression of a
functional hypoxia-inducible factor 1
 
 
 
 (HIF1
 
 
 
) protein re-
sulting in a stimulation of 
 
Vegf
 
 expression. Interestingly,
we report that the melanocyte-speciﬁc transcription factor,
microphthalmia-associated transcription factor (MITF),
binds to the 
 
Hif1a
 
 promoter and strongly stimulates its
I
 
transcriptional activity. Further, MITF “silencing” abro-
gates the cAMP effect on 
 
Hif1a
 
 expression, and overex-
pression of MITF in human melanoma cells is sufﬁcient to
stimulate 
 
HIF1A
 
 mRNA. Our data demonstrate that 
 
Hif1a
 
is a new MITF target gene and that MITF mediates the
cAMP stimulation of 
 
Hif1a
 
 in melanocytes and melanoma
cells. Importantly, we provide results demonstrating that
HIF1 plays a pro-survival role in this cell system. We
therefore conclude that the 
 
 
 
-MSH/cAMP pathway, using
MITF as a signal transducer and HIF1
 
 
 
 as a target, might
contribute to melanoma progression.
 
Introduction
 
In the skin physiological system, 
 
 
 
-melanocyte stimulating hor-
mone (
 
 
 
-MSH) constitutes an important keratinocyte secreted
factor in response to the UV radiation of sunlight. Keratinocytes
account for the main epidermal cell type, and melanocytes, situ-
ated at the basal layer of the epidermis, are responsible for melanin
synthesis and skin color. In melanocytes, 
 
 
 
-MSH, through the
binding to the melanocortin-1 receptor (MC1R) and up-regulation
of the cAMP pathway, induces pigmentation by controlling sev-
eral parameters of melanocyte differentiation such as melanin
synthesis (melanogenesis) (Buscà and Ballotti, 2000), dendrite
outgrowth (Buscà et al., 1998), and melanosome transport, required
for melanin distribution within the skin (Passeron et al., 2004).
The 
 
 
 
-MSH/MC1R/cAMP signaling pathway has also
been reported to influence melanoma biology, but in contrast to
the undisputed role of cAMP in promoting pigmentation, data
relating cAMP to melanoma progression currently appear con-
tradictory. 
 
 
 
-MSH has been reported to inhibit melanoma
growth and adhesion (Robinson and Healy, 2002), suggesting
that a compromised cAMP signaling could favor melanoma
progression. In agreement with this hypothesis, variants of
MC1R with altered cAMP response have been associated with
high melanoma susceptibility (Valverde et al., 1995; Robinson
and Healy, 2002). In contrast, 
 
 
 
-MSH and cAMP increase 
 
c-met
 
expression in melanoma cells and could thereby favor the mel-
anoma metastatic potential (Rusciano et al., 1999). Consis-
tently, the CREB/ATF family of transcription factors that
function downstream of the cAMP pathway have also been re-
ported to act as survival factors and contribute to the malignant
phenotype (for review see Poser and Bosserhoff, 2004).
The cAMP-triggered mechanisms controlling melano-
cyte pigmentation have been thoroughly investigated. cAMP,
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through PKA and CREB activation, increases the expression
of the melanocyte-specific form of microphthalmia-associ-
ated transcription factor (MITF) (Bertolotto et al., 1998a), a
basic helix-loop-helix transcription factor that plays a key
role not only in melanin synthesis, but also in melanocyte de-
velopment and survival (Hodgkinson et al., 1993; Hughes et
al., 1993).
Noteworthy, in melanocytes and melanoma cells, cAMP
regulates several signaling pathways that control multiple bio-
logical functions. Indeed, cAMP inhibits the phosphatidylino-
sitol 3-kinase/AKT pathway that influences both differentiation
and survival of melanocytes (Buscà et al., 1996; Khaled et al.,
2002; Larribere et al., 2004). Further, 
 
 
 
-MSH and cAMP stim-
ulate the MAPK pathway (Englaro et al., 1995; Buscà et al.,
2000) through B-Raf activation. Indeed, B-Raf has been re-
cently found mutated and activated in a vast majority of mela-
noma (Davies et al., 2002).
To further investigate the molecular events elicited by
 
 
 
-MSH and cAMP in melanocytes and better understand the
implication of its signaling in melanoma biology, we per-
formed a large-scale gene screening by using a DNA mi-
croarray (Moreilhon et al., 2004). We used B16 mouse mela-
noma cells to analyze the overall modification of gene
expression after 24 h of treatment with the cAMP-elevating
agent forskolin.
Very interestingly, we found that cAMP stimulates the
expression of the 
 
Hif1a
 
 gene whose protein product, hypoxia-
inducible factor 1
 
 
 
 (HIF1
 
 
 
), constitutes the 
 
 
 
 subunit of the
HIF1, a master regulator of oxygen homeostasis. After dimer-
ization with HIF1
 
 
 
 (also named ARNT), HIF1
 
 
 
 binds to a con-
sensus sequence 5
 
 
 
-RCGTG-3
 
 
 
 called hypoxia-responsive ele-
ment (HRE), and controls the expression of several genes
involved in many aspects of cancer progression, including met-
abolic adaptation, apoptosis resistance, angiogenesis, invasion,
and metastasis (for review see Semenza, 2002). To date, HIF1
 
 
 
has been shown to be tightly regulated by multiple post-transla-
tional modifications that mainly control the protein stability
through the ubiquitin–proteasome pathway (Brahimi-Horn et
al., 2001; Berra et al., 2003).
In this paper, we show that cAMP transcriptionally reg-
ulates 
 
Hif1a
 
 gene expression because the cAMP-elevating
agent forskolin increases 
 
Hif1a
 
 mRNA and regulates 
 
Hif1a
 
promoter activity. cAMP increases the expression of a func-
tional HIF1
 
 
 
 protein that results in the induction of 
 
Vegf
 
 ex-
pression. Furthermore, the effect of cAMP on HIF1
 
 
 
 is re-
stricted to melanocyte cells. This cell specificity is given by
MITF that binds to the 
 
Hif1a
 
 promoter and strongly stimu-
lates its transcriptional activity. MITF silencing abrogates the
effect of cAMP on HIF1
 
 
 
 expression, and infection of hu-
man melanoma cells with an MITF-encoding adenovirus in-
creases 
 
Hif1a
 
 mRNA expression, clearly demonstrating that
 
Hif1a
 
 is a new MITF target gene. Because we demonstrate
that HIF1
 
 
 
 plays a pro-survival role in melanoma and we
suggest that it is involved in neovascularization, we conclude
that the 
 
 
 
-MSH/cAMP pathway, through a molecular cas-
cade sequentially involving MITF and HIF1
 
 
 
, might contrib-
ute to melanoma development.
 
Results
 
Hif1a
 
 gene expression is induced by the 
cAMP pathway in B16 melanoma cells
 
In an attempt to screen for cAMP-induced genes in melanocyte
cells, we used a laboratory-designed DNA microarray (Moreil-
hon et al., 2004) described in the Materials and methods sec-
tion. B16 mouse melanoma cells were treated (or not) with the
cAMP-elevating agent forskolin for 24 h. Total mRNAs were
extracted, labeled, and hybridized with microarray slides.
The induction of several already-known cAMP-regulated
genes validated our array approach. The biochip analysis iden-
tified several cAMP-regulated genes which protein products
have previously been clearly involved in melanogenesis (Table
I) such as tyrosinase, tyrosinase-related protein 1, Mitf, or pro-
teins involved in melanosome transport such as Myosin Va and
Rab27a. These results were confirmed by real-time quantitative
PCR (Table I).
Surprisingly, cAMP clearly induced the expression of
 
Hif1a
 
 gene (threefold stimulation; Table I). Due to the pivotal
role of HIF1 transcription factor in cancer progression, we de-
cided to thoroughly investigate the molecular mechanisms gov-
erning 
 
Hif1
 
 
 
 gene regulation by cAMP in melanoma cells.
 
cAMP induces a functional HIF1
 
 
 
 protein
 
Western blot experiments using a specific anti HIF1
 
 
 
 antibody
showed that HIF1
 
 
 
 protein slightly increased at 6 h and
reached its maximal levels upon 24 h of forskolin treatment.
After 48 h, HIF1
 
 
 
 protein expression remained stable (Fig. 1 A).
 
 
 
-MSH, a physiological activator of the cAMP pathway in
melanocytes, also increased HIF1
 
 
 
 protein levels similarly to
hypoxia (24 h), which was used as a positive control of HIF1
 
 
 
protein induction. In addition, cAMP plus hypoxia appeared to
have additive effects (Fig. 1 B). The same results were ob-
tained using normal human melanocytes (NHM). In this case
we used Co
 
2
 
 
 
, to mimic hypoxia (Berra et al., 2003), as a con-
trol (Fig. 1 C). Therefore, HIF1
 
 
 
 protein increased upon cAMP
up-regulation in B16 melanoma cells and NHM independently
of the oxygen context.
To evaluate whether the cAMP-induced HIF1
 
 
 
 formed a
functional transcriptional complex, we measured the activity of
the 3-HRE-LUC reporter gene (Berra et al., 2003).
 
Table I. 
 
cAMP induces 
 
Hif1a
 
 mRNA expression
Gene Microarray Q-PCR
 
Tyr
 
 6.32 
 
 
 
 1.0 3.32 
 
 
 
 0.4
 
Tyrp1
 
1.8 
 
 
 
 0.4 2.8 
 
 
 
 0.5
 
MyoVa
 
8.70 
 
 
 
 0.3 2.9 
 
 
 
 0.2
 
Rab27a
 
2.27 
 
 
 
 1.0 3.05 
 
 
 
 0.2
 
Mitf
 
 3.71 
 
 
 
 0.9 4.92 
 
 
 
 0.9
 
Hif1a
 
3.05 
 
 
 
 1.0 2.85 
 
 
 
 0.4
 
Microarray analysis performed as described in the Materials and methods
section. The results correspond to the fold stimulation of genes stimulated in B16
mouse melanoma cells after 24 h of treatment with the cAMP-elevating agent,
forskolin (20 
 
 
 
M). The values are the average of four independent biochip
experiments. Real time quantitative PCR analysis (Q-PCR) was performed in the
same conditions. The results are represented as the fold stimulation after forskolin
treatment and correspond to the average of five independent experiments. 
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The results obtained showed that the 3-HRE-LUC con-
struct was responsive (by a five- to sixfold stimulation) to
cAMP in B16 melanoma cells. Co
 
2
 
 
 
 stimulation was used as a
positive control and again the effect of Co
 
2
 
 
 
 and cAMP ap-
peared additive (Fig. 1 D).
Among the multiple HIF1 target genes containing an
HRE core sequence in their promoter region, 
 
Vegf
 
 has been
largely studied because it is required for tumor angiogenesis.
We therefore analyzed the effects of cAMP in endogenous
 
Vegf
 
 expression in B16 cells. Real-time quantitative PCR ex-
periments showed that forskolin increased vascular endothelial
growth factor (VEGF) mRNA in these melanocyte cells. As ex-
pected, Co
 
2  highly induced Vegf and enhanced the cAMP re-
sponse (Fig. 1 E). Together, these results demonstrate that
cAMP induced a functional HIF1  protein.
cAMP up-regulation if Hif1a gene 
transcription is cell specific
To further elucidate the mechanisms by which cAMP regulates
HIF1  expression, we performed Hif1a promoter activity as-
says. An Hif1a promoter fragment cloned upstream of the lu-
ciferase reporter gene (Wenger et al., 1998) was transfected in
B16 melanoma cells. The promoter activity, monitored by the
luciferase levels, increased upon cAMP treatment (Fig. 2 A).
The same experiment was performed in NIH-3T3 fibroblasts,
and we observed that forskolin had no impact on Hif1a pro-
moter activity (Fig. 2 A). Furthermore, in these cells cAMP de-
creased Hif1a mRNA amount (Fig. 2 B). At the protein level,
cAMP treatment did not affect HIF1  expression in NIH-3T3
fibroblasts (Fig. 2 C), whereas the control Co
2  induced the
protein expression. A comparison of the functional HIF1 
protein levels between B16 melanocyte cells and NIH-3T3
nonmelanocyte cells was performed using the 3-HRE-LUC re-
porter system (Fig. 2 D). We observed that although forskolin
significantly increased the reporter transactivation in B16 cells,
this did not occur in NIH-3T3 fibroblasts. In contrast, Co
2 
treatment increased luciferase expression in both cell lines.
These results indicate that cAMP increases Hif1  gene tran-
scription in a melanocyte cell–specific manner.
MITF binds and transactivates the 
Hif1a promoter
The cell specificity of HIF1  induction by cAMP prompted us
to hypothesize the existence of specific molecular mechanisms
responsible for HIF1  regulation in melanocytes and mela-
noma cells. Sequence analysis of the Hif1a promoter (Wenger
et al., 1998) revealed 10 core E-box consensus sequences
composed by the CANNTG motif (Fig. 3 A). Noteworthy,
among these 10 E-boxes, 2 perfectly match with the motif of
MITF binding (CACGTG) (Aksan and Goding, 1998). We
therefore investigated whether MITF could account for the
cell-specific cAMP regulation of HIF1  expression. To evalu-
ate the MITF binding to the Hif1a promoter region in the en-
dogenous chromatin context, we performed chromatin immu-
noprecipitation assays (Fig. 3 B). B16 cells were stimulated
with the cAMP-elevating agent forskolin for 5 h to maximally
increase MITF protein expression (Bertolotto et al., 1998a).
Chromatin complexes were immunoprecipitated with an anti-
Figure 1. cAMP increases the expression of a functional HIF1  protein in melanocyte cells. (A) B16 cells were stimulated for 6, 24, and 48 h with
forskolin (FK) and cell extracts were subjected to Western blot analysis to detect HIF1  protein levels. A control of the protein loading was performed by
detecting ERK2. (B) The same experiment was performed by stimulating B16 cells either with forskolin (FK) or  -MSH ( -M) for 24 h. Cells were incubated,
either in normal oxygen conditions (Normoxia, 20% O2) or maintained under hypoxia (1–2% O2). (C) A Western blot to analyze HIF1  protein expres-
sion was performed using extracts from normal human melanocytes. Cells were starved and treated with forskolin (FK) for 24 h or with cobalt (Co
2 ) to
mimic hypoxia as a positive control. (D) B16 cells were transfected with the 3-HRE-LUC reporter construct and treated (or not) (NS) with forskolin (FK) for at
least 36 h, with cobalt (Co
2 ) for 12 h, or with both (Co
2    FK). Luciferase activity was normalized by the  -galactosidase activity and data are ex-
pressed in fold stimulation of the basal 3-HRE-LUC activity. Data are means   SE of five experiments performed in triplicate. (E) Real-time quantitative PCR
to detect Vegf mRNA levels on total RNA extracts from B16 cells treated as described in D.JCB • VOLUME 170 • NUMBER 1 • 2005 52
MITF antibody and a PCR was performed using specific prim-
ers to the mouse Hif1a promoter region. As shown in Fig. 3 B,
we detected a specific amplification of the Hif1a promoter re-
gion that increased after forskolin treatment. As a positive
control, we used specific primers spanning the tyrosinase pro-
moter region, which is well known to bind MITF. As ex-
pected, the tyrosinase promoter amplification also increased
upon cAMP exposure. A specific band corresponding to the
Hif1a or tyrosinase promoter was detected when using mouse
genomic DNA. In the absence of antibody, no specific ampli-
fication was observed. Another negative control was per-
formed by applying 40 cycles of PCR to the MITF immuno-
precipitates using a primer pair to the mouse GAPDH. As
expected for a sequence that does not present MITF binding
sites, no GAPDH amplification was observed while a clear
PCR band was detected using the genomic DNA as a template
(Fig. 3 B, bottom panel). We therefore conclude that MITF
binds to the Hif1a promoter in the chromatin context of B16
melanoma cells.
Next, we evaluated whether the MITF binding transacti-
vated Hif1a promoter. Thus, we cotransfected the reporter con-
struct encoding the Hif1a promoter fragment, together with dif-
ferent amounts of a plasmid encoding the MITF transcription
factor. We clearly observed that MITF highly transactivated
the Hif1a promoter activity in a dose-dependent manner (Fig.
3 C), whereas two other transcription factors of the same basic
helix-loop-helix family, like USF and myc, did not. The func-
tionality of the constructs encoding USF and myc was verified
by their capacity to transactivate specific target promoters
(unpublished data).
Next, we analyzed whether MITF could stimulate the ex-
pression of the endogenous Hif1a gene. In this aim we infected
Mewo human melanoma cells either with an empty adenovirus
(pCDNA3) or an adenovirus encoding MITF. 48 h after infec-
tion, total mRNAs were extracted and subjected to real-time
quantitative PCR to control MITF overexpression and evaluate
Hif1a expression. As shown in Fig. 3 D, MITF mRNA levels
increased after MITF infection ( 4.6-fold) as expected, and
Hif1a mRNA expression was significantly induced by MITF
overexpression ( 3.7-fold).
To elucidate whether MITF could also transactivate the
Hif1a promoter in a nonmelanocyte cell context, we cotrans-
fected NIH-3T3 with this promoter together with the plasmid
encoding MITF. The results obtained revealed that MITF sig-
nificantly increased the Hif1a promoter activity ( 3.5-fold)
(Fig. 3 E).
Figure 2. cAMP induces HIF1  expression in a cell-specific manner. (A) B16 cells and NIH-3T3 cells were transfected with a fragment of the Hif1a gene
promoter cloned upstream of the luciferase reporter gene, and were then stimulated (or not) (NS) with forskolin (FK). Luciferase activity was normalized by
the  -galactosidase activity and results are represented as the fold stimulation of the cAMP-activated promoter compared with the basal value. (B) Real-time
quantitative PCR to detect Hif1a mRNA levels was performed on total RNAs from NIH-3T3 fibroblasts nonstimulated (NS) or treated for 24 h with forskolin
(FK). (C) NIH-3T3 extracts were subjected to Western blot analysis to detect HIF1  protein levels after cell stimulation with forskolin (FK) for 24 h, or cobalt
(Co
2 ) for 12 h. ERK2 levels show a control of the gel protein loading. White lines indicate that intervening lanes have been spliced out. (D) 3-HRE-LUC
reporter assay on B16 and NIH-3T3 cells nonstimulated (NS) of stimulated with forskolin (FK) or cobalt (Co
2 ).cAMP REGULATION OF HIF1A EXPRESSION THROUGH MITF • BUSCÀ ET AL. 53
Together, these results strongly indicate that MITF binds
to the proximal region of the Hif1a promoter and stimulates its
transactivation leading to increased expression of Hif1a mRNA
in melanoma cells. Moreover, MITF seems to be sufficient to
transactivate the Hif1a promoter in nonmelanocyte cells.
MITF mediates the effect of cAMP on 
Hif1a promoter activity and protein 
expression
To evaluate whether MITF was required for the cAMP induc-
tion of the Hif1a gene expression, B16 cells were cotransfected
Figure 3. MITF binds to the Hif1a promoter and induces Hif1  gene expression. (A) Schematic representation of the Hif1a promoter. Black arrow denotes
the ubiquitously expressed 1.2 exon (Wenger et al., 1998). Vertical rectangles and the associated numbers represent the several E-boxes found in this pro-
moter fragment and their localization within the sequence. Note that E2 and E7 match perfectly with the previously described MITF binding sequence
(CACGTG) (Weilbaecher et al., 1998). (B) Chromatin immunoprecipitations were performed on extracts from nonstimulated (NS) and 5-h forskolin-stimulated
(FK) B16 melanoma cells as described in Materials and methods. Immunoprecipitation was performed using a specific anti-MITF antibody and primers span-
ning the Hif1a or the tyrosinase promoter region were used for the PCR amplification. A control of PCR amplification was performed using mouse genomic
DNA, which showed a 300-bp and a 900-bp band corresponding to the amplification of the Hif1a and tyrosinase promoter regions, respectively. Another
control was performed using a primer pair to the mouse GAPDH (150-bp amplicon). (C) Hif1a promoter activity after cotransfection of B16 cells with the
Hif1a promoter fragment together with an empty plasmid (pcDNA3), a vector encoding MITF transcription factor, and two other constructs encoding USF
and MYC. As a control of the promoter activation, cells were stimulated with forskolin (FK). Results are shown as the fold stimulation compared with the
basal nonstimulated promoter activity (NS). (D) Real-time quantitative PCR analysis to detect Mitf and Hif1a mRNA levels after infection of Mewo (human
melanoma cells) with either an empty adenovirus (Adeno-pCDNA3) or an adenovirus encoding MITF. (E) Hif1a promoter activity after cotransfection of
NIH-3T3 fibroblasts with an empty vector (pCDNA3) or a construct encoding MITF. Cells were next stimulated (or not) (NS) with forskolin (FK) for 24 h.JCB • VOLUME 170 • NUMBER 1 • 2005 54
with the Hif1a promoter fragment together with a dominant-
negative mutant of MITF (MITF DNT) lacking the NH2-ter-
minal transactivation domain, and cells were then stimulated
with forskolin. Interestingly, we observed that MITF DNT
completely abolished the cAMP stimulation of the Hif1a pro-
moter activity (Fig. 4 A). To further strengthen the MITF
specificity of such response, we performed the same experi-
ment by using specific small interference RNAs (siRNAs) tar-
geting MITF. As a control, cells were cotransfected with the
Hif1a promoter together with a nonrelevant siRNA (control
siRNA). Fig. 4 B shows that MITF silencing clearly inhibited
the cAMP-induced Hif1a promoter transactivation, thereby
indicating that MITF mediates the cAMP effects on Hif1a
gene expression.
Figure 4. MITF is required for cAMP-dependent
Hif1a expression. (A) Hif1a promoter activity
assays on B16 cells cotransfected with either
an empty vector (pCDNA3) or a construct en-
coding a dominant-negative mutant of MITF
(MITF-DNT) and treated (or not) (NS) with the
cAMP-elevating agent forskolin (FK). Results
are expressed as the fold stimulation of the lu-
ciferase activity compared with the pcDNA3-
transfected nonstimulated condition. (B) The
same experiment was performed by cotrans-
fecting the Hif1a promoter with either an
siRNA-targeting MITF (siRNA-MITF) or a non-
relevant siRNA (siRNA-control).
Figure 5. MITF mediates the cAMP increase of HIF1  protein. (A) Immunofluorescence study of B16 cells transfected with a nonrelevant siRNA (siRNA
control) (left), an siRNA-targeting MITF (middle), and an siRNA to HIF1  (right). Cells were either left nonstimulated (NS) or were stimulated for 24 h with
the cAMP-elevating agent forskolin (FK). MITF protein expression was detected with the C5 monoclonal primary antibody and a secondary fluorescein-con-
jugated antibody (green), HIF1  was labeled with a primary pAb and a secondary Texas red–conjugated antibody (red), and nuclei were stained with
bisbenzidine (blue). Bar, 20  M. (B) Western blot analysis of HIF1  protein from B16 cell extracts treated as in A. Cells were stimulated with Co
2  for 12 h
as a positive control. ERK2 detection showed the equal protein loading of each gel lane. (C) Real-time quantitative PCR to detect Vegf mRNA levels on
total RNA extracts from B16 cells transfected and treated as described in A. A transfection condition using an siRNA to silence PHD2 (to increase HIF1 
protein) was added.cAMP REGULATION OF HIF1A EXPRESSION THROUGH MITF • BUSCÀ ET AL. 55
To study the impact of MITF on the endogenous HIF1 
protein, the same siRNA approach was undertaken. The ex-
pression of MITF and HIF1  proteins was then monitored by
immunofluorescence using specific antibodies to MITF (green
fluorescein labeling) and HIF1  (Texas red labeling). After 24 h
of stimulation with the cAMP-elevating agent forskolin we ob-
served an increased nuclear labeling corresponding to MITF
expression, as well as a significant increase in HIF1  protein
(Fig. 5 A). As expected, MITF silencing led to an important
inhibition of cAMP-dependent MITF induction as well as the
cAMP-induced HIF1  expression. In the presence of an
siRNA to silence HIF1  expression, although cAMP elevat-
ing agents expectedly increased MITF expression, HIF1 
expression was inhibited in both basal and cAMP conditions.
A Western blot analysis of samples treated in parallel (Fig. 5 B)
confirmed the same results in a more quantitative way. We
therefore demonstrate that MITF controls HIF1  transactiva-
tion and constitutes a critical step in the cAMP up-regulation
of HIF1  expression.
MITF and HIF1  are responsible for the 
cAMP-dependent Vegf mRNA induction
Vegf being a well-known target gene of HIF1  involved in an-
giogenesis and tumor growth, we analyzed whether MITF and
HIF1  could account for the cAMP-induced Vegf expression in
B16 melanoma cells. Quantitative PCR experiments were per-
formed on mRNAs extracted from B16 cells transfected with a
control siRNA or siRNAs targeting MITF or HIF1  to deplete
cells from these transcription factors, as well an siRNA to si-
lence HIF prolyl-hydroxylase 2 (PHD2), which is specifically
responsible for HIF1  protein degradation (Berra et al., 2003).
We observed that MITF or HIF1  silencing inhibited the basal
as well as the forskolin-induced Vegf expression, whereas
PHD2 cell depletion, which increased HIF1  protein levels
(unpublished data), exerted the opposite effect by significantly
increasing the Vegf mRNA levels.
These data are consistent with Vegf being a MITF-HIF1 
target gene in our melanoma model, and show that the cAMP-
induced Vegf expression is mediated by the MITF-HIF1  cascade.
Figure 6. HIF1  plays a pro-survival role in B16 melanoma cells. (A) Immunofluorescence study to detect the presence of cleaved caspase-3 in B16 cells
nonstimulated (NS) or stimulated for 24 with forskolin (FK), and nontreated ( St) or treated with staurosporin ( St) for 6 h. Bar, 40  M. (B) Immuno-
fluorescence analysis of B16 cells transfected with a nonrelevant siRNA (siRNA-Ctrol) or an siRNA to invalidate HIF1 . Cleaved caspase-3 was labeled
with a secondary Texas red–conjugated antibody (red) and HIF1  protein was detected by an mAb and a secondary FITC-conjugated secondary one
(green). Nuclei were labeled with bisbenzidine (blue). Bar, 20  M.JCB • VOLUME 170 • NUMBER 1 • 2005 56
HIF1  plays a pro-survival role 
in melanoma
To investigate the physiological relevance of HIF1  induction
in melanocyte cells, and taking into account the role attributed
to HIF1 factor in cell survival, we evaluated the putative impli-
cation of HIF1  in this feature of melanoma cell physiology.
For that we treated B16 melanoma cells with stauro-
sporin, considered a strong cell death inducing agent, and we
used an immunofluorescence analysis to detect the presence of
cleaved caspase-3 as a marker of cell death. We observed that
treatment with staurosporin for 6 h greatly induced caspase-3
cleavage in our cell system (Fig. 6 A). We next pretreated B16
cells for 24 h with forskolin to increase HIF1 . We inter-
estingly observed that cAMP strongly reduced the cleaved cas-
pase-3 labeling thereby indicating that cAMP inhibits the stau-
rosporin-induced cell death (Fig. 6 A).
Then we used an siRNA approach to dissect the contribu-
tion of HIF1  in this cell death protection. B16 cells were
transfected with a nonrelevant siRNA or an siRNA to invali-
date Hif1a expression. Cells were next treated (or not) with for-
skolin for 24 h, and they were finally exposed to 6 h of stauro-
sporin. Fig. 6 B shows that in control siRNA–transfected cells,
forskolin increased HIF1  protein expression and decreased
caspase-3 cleavage, whereas in siRNA-Hif1 –transfected
cells, the forskolin-dependent decrease of caspase-3 cleavage
was nearly abolished. This result indicates that HIF1  protects
cells from the staurosporin-induced cell death, thereby suggest-
ing a pro-survival role of HIF1 in the melanoma cell model.
Discussion
In the present work, we have identified Hif1a as a new cAMP-
induced gene in melanoma cells and we have characterized the
molecular mechanisms underlying this regulation.
We demonstrate for the first time that cAMP regulates
Hif1a at a transcriptional level, leading to increased expression
of HIF1  mRNA and protein. HIF1  forms a HIF1 complex
that is functional and able to transactivate target genes such
as Vegf. Very interestingly, HIF1  induction by cAMP is
restricted to melanocyte cells, prompting us to propose a cell-
specific regulation through the melanocyte-specific transcrip-
tion factor MITF. We demonstrate that MITF binds and trans-
activates the Hif1a promoter, and the overexpression of MITF
is sufficient to increase Hif1a mRNA levels. Furthermore, by
silencing MITF or Hif1  expression, we show that cAMP-
induced HIF1  expression is mediated by MITF, and that the
MITF/HIF1  pathway mediates the cAMP induction of Vegf
expression (a model illustrating these conclusions is shown in
Fig. 7). We therefore define Hif1a as a new MITF target gene
and we provide data revealing the pro-survival role of the
MITF-HIF1 cascade in melanoma cells.
HIF1  activation triggered by hypoxia is mainly governed
by post-translational modifications involving hydroxylation of
specific amino acid residues in the HIF1  subunit (Berra et al.,
2003). Indeed, O2-dependent prolyl hydroxylation regulates
proteasome-mediated destruction of HIF1 , whereas asparagi-
nyl hydroxylation blocks the interaction with the p300/CBP co-
activators (for review see Lando et al., 2002). In addition to
hypoxia, growth factors, vaso-active hormones, cytokines, and
tumor suppressor mutations also stimulate HIF1  synthesis
via activation of the phosphatidylinositol 3-kinase or MAPK
pathways (Zhong et al., 2000; Zundel et al., 2000; Fukuda et
al., 2002).
As a novelty, our study clearly demonstrates that cAMP
regulates HIF1  at a transcriptional level independently of the
oxygen context. To date, very few works have described a reg-
ulation of Hif1a mRNA (Jiang et al., 1997; Blouin et al., 2004;
Liu et al., 2004). Nevertheless, no studies have so far dissected
or identified a transcriptional mechanism accounting for
HIF1  gene expression. In our work, we go further in the
characterization of the molecular mechanisms that regulate
Hif1a gene transcription because we identify for the first time
a transcription factor (i.e., MITF) that binds and functionally
transactivates the Hif1a promoter and controls this gene ex-
pression independently of the oxygen conditions.
We also show that cAMP and hypoxia have additive ef-
fects on HIF1  protein levels. Both stimuli via transcriptional
and post-translational mechanisms, respectively, cooperate to
highly induce HIF1  protein. It is tempting to propose that, in-
dependently of the oxygen availability, MITF acts as a fine
modulator of the final HIF1  protein levels to modify the bio-
logical fate of melanocytes and melanoma cells.
In addition to regulating Hif1a transcription, we could
imagine that cAMP, like hypoxia, might act on HIF1  protein
stabilization by modulating its hydroxylation or enhancing its
translation. This does not seem to be the case because MITF in-
hibition by a dominant-negative mutant or a specific siRNA
completely abolishes the cAMP-induced HIF1  protein expres-
Figure 7. Model for the mechanisms of cAMP induction of HIF1  expression.
 -MSH, by up-regulating the cAMP pathway, increases MITF expression.
MITF binds and transactivates the Hif1a promoter, thereby increasing the
expression of Hif1a gene and protein in a melanocyte cell–specific manner.
HIF1  dimerizes with HIF1  to constitute a functional HIF1 transcription
factor that is capable of activating target genes such as Vegf and up-
regulate other genes involved in melanocyte cell survival and angiogenesis
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sion. However, we cannot definitively rule out the possibility
that cAMP might also regulate HIF1 DNA binding or transacti-
vation potential by controlling other HIF1  post-translational
modifications such as phosphorylation. In support of that, we
have previously described that cAMP specifically activates the
MAPK pathway in melanocytes (Englaro et al., 1995; Buscà et
al., 2000) and the transcriptional activity of HIF1 has been
reported to be stimulated upon phosphorylation by MAPK
(Richard et al., 1999; Suzuki et al., 2001; Lee et al., 2002).
HIF1  has a broad impact on gene expression ( 60 di-
rect target genes have been identified), making it a crucial ele-
ment in the regulation of many cell features going from cell
proliferation to motility and apoptosis. Furthermore, HIF1 
has a special impact on cancer progression because of its
effects on angiogenesis and glucose metabolism (Semenza,
2003). Further, HIF1 mediates tumor cell adaptive response to
hypoxia by regulating genes implicated in cell survival (Se-
menza 2001). In nontumor cells, a recent work by Xie et al.
(2005) also involves HIF1 as a survival factor that protects
neurons from NGF deprivation-induced cell death. In contrast,
in other contexts HIF1  has been shown to participate in hyp-
oxia-induced cell death via interaction with p53 (Halterman
and Federoff, 1999) or modulation of several pro-apoptotic tar-
gets such as NIP3 (Bruick, 2000), Noxa (Kim et al., 2004),
BNIP3 and NIX (Sowter et al., 2001), RTP801 (Shoshani et al.,
2002), and the recently described HGTD-P (Lee et al., 2004).
In this case, MITF, by regulating HIF1  expression, would
rather favor cell death. In our melanoma cell system, we find
that HIF1 plays a pro-survival role, as observed by the inhibi-
tion of the staurosporin-induced caspase-3 cleavage. We can
therefore imagine that the cAMP/MITF/HIF1 pathway might
contribute to higher cell viability and resistance to any putative
physiological or environmental stresses such as UV exposure,
for example.
The fact that cAMP increases Vegf mRNA in our mela-
noma cells also leads us to hypothesize an angiogenic role of the
cAMP/MITF/HIF1 cascade. In agreement with this hypothesis,
UV radiation has been reported to increase cutaneous angiogen-
esis (Bielenberg et al., 1998) and nevus growth (Menzies et al.,
2004). Because  -MSH production in skin is stimulated upon
UV radiation, we could imagine that  -MSH, by up-regulating
the cAMP-MITF-HIF1 pathway could participate to the angio-
genic and growth-promoting effects of UV radiation.
Thus, together, these observations suggest that the stimu-
lation of HIF1  expression by cAMP and MITF might facilitate
both melanoma survival, neo-vascularization, and metabolic ad-
aptation, thereby favoring the development of these tumors.
Although the role of MITF in survival and development of
melanocyte precursors has been clearly documented, the growth
and survival functions of MITF in mature melanocytes and mel-
anoma cells remain a matter of debate. Indeed, it has been dem-
onstrated that overexpression of MITF into a melanoma cell line
results in slower xenograft tumor growth (Selzer et al., 2002),
and MITF was recently shown to inhibit cell growth by activat-
ing the cell cycle inhibitor INK4A (Loercher et al., 2005) as
well p21
CIP1 expression (Carreira et al., 2005). However, recent
reports have shown that MITF is a melanoma survival factor
presumably through the up-regulation of the anti-apoptotic gene
BCL2 (McGill et al., 2002) and promotes melanoma cell growth
by stimulating CDK2 expression (Du et al., 2004).
All of these data suggest that MITF, as well HIF1 , can
elicit opposite cellular responses. The decision between pro-
survival and growth inhibition might be dictated by the cellular
context, the extracellular signals, the microenvironment, or the
mutational status of melanoma. In our case, cAMP constitutes
a signal that clearly tilts the balance toward survival and pre-
sumably angiogenesis and melanoma growth.
In conclusion, here we show for the first time a transcrip-
tional up-regulation of HIF1  by the melanocyte-specific tran-
scription factor MITF, thereby establishing a possible link
between MITF and melanoma survival and vascularization.
Taking into account the functional plasticity of both MITF and
HIF1 , further studies are underway to elucidate the precise
physiological relevance of the MITF-HIF1  cascade in mela-
noma development. Modulation of such regulatory mechanisms
could provide novel therapeutic approaches to this aggressive
and metastatic cancer.
Materials and methods
Cell culture
B16/F10 (mouse melanoma cells), Mewo (human melanoma cells), and
NIH 3T3 (mouse fibroblasts) were cultured in DME (GIBCO BRL) supple-
mented with 7% FBS (Hyclone Laboratories) and penicillin/streptomycin
(100 IU/50  g/ml; Sigma-Aldrich) in a humidified atmosphere contain-
ing 5% CO2 in air at 37 C. Primary human melanocytes (NHM) were ob-
tained from neonatal foreskins of Caucasian individuals, and grown in
MCDB medium (GIBCO BRL) according to a modification of the method of
Eisinger and Marko (1982) and Aberdam et al. (1993). Before cAMP
treatment, NHM were depleted in forskolin for at least 24 h.
When indicated, cells were treated with forskolin (20  M),  -MSH
(1  M), or cobalt (200  M) to mimic hypoxia. To induce caspase-3 cleav-
age, cells were treated with 1  M staurosporin (Calbiochem) for 6 h. Hyp-
oxic conditions were produced by incubation of cells in a sealed “Bug-
Box” anaerobic workstation (Ruskin Technologies). The oxygen in this
workstation was maintained at 1–2%, with the residual gas mixture being
93–94% nitrogen and 5% CO2.
Plasmids, adenovirus, siRNAs, and PCR oligonucleotide sequences
The plasmid encoding the mouse Hif1a promoter fragment upstream of
the luciferase reporter gene was provided by Dr. R. Wenger (University
of Zürich, Zürich, Switzerland). The 3-HRE-LUC reporter vector contains
three copies of the HRE from the erythropoietin promoter cloned upstream
of a minimal thymidine kinase promoter and the luciferase reporter gene
(Berra et al., 2003). The plasmids encoding the mouse MITF and MIT-
FDNT are described in Bertolotto et al. (1998a). The adenovirus encod-
ing MITF is reported in Gaggioli et al. (2003).
The DNA sequence corresponding to the siRNA-targeting Mitf is:
5 -GGTGAATCGGATCATCAAG-3 ;  Hif1a: 5 -CCTATATCCCAATGGAT-
GATG-3 . As nonrelevant siRNAs (control siRNAs) we used the siLUC: 5 -
CGTACGCGGAATACTTCGA-3  and the Drosophila melanogaster Hif1a
(SIMA): 5 -CCTCATCCCGATCGATGATG-3  described in Berra et al.
(2003). The mouse siRNA sequence targeting PHD2 was: 5 -GAACT-
CAAGCCCAATTCAGTT-3 .
The oligonucleotides to amplify the Hif1a and tyrosinase promoter
regions were: 5 -CACGGGCACGAAGTGTTCCTTTG-3  (forward) and 5 -
GCTCAGCCGCACCCGTCACT-3  (reverse) for Hif1a and 5 -GATC-
TCTAAATACAACAGGCT-3  (forward) and 5 -TCATACAAAATCTGCAC-
CAA-3  (reverse) for tyrosinase, and to amplify GAPDH we used: 5 -TGG-
TATGACAACGAATTTG-3  (forward) and 5 -TCTACATGGCAACTGT-
GAGG-3  (reverse).
The oligonucleotide sequences corresponding to mouse Hif1a,
Mitf, tyrosinase, tyrosinase-related protein 1, MyoVa and Rab27a, and
human MITF and HIF1A used for real-time quantitative PCR are available
upon request.JCB • VOLUME 170 • NUMBER 1 • 2005 58
Antibodies
The mAb to MITF (C5) was obtained from Dr. D. Fisher (Dana Farber Can-
cer Institute, Boston, MA; Weilbaecher et al., 1998). The polyclonal anti-
MITF antibody used for the chromatin immunoprecipitation assays is de-
scribed in Bertolotto et al. (1996). The rabbit anti-HIF1  (antiserum 2087)
is described in Richard et al. (1999) and the monoclonal anti-HIF1  anti-
body used for the HIF1 /caspase-3 double labeling was from Abcam.
The pAb to cleaved caspase-3 was from Cell Signaling. The pAb anti-extra-
cellular signal-regulated kinase 2 (ERK2) is from Santa Cruz Biotechnolo-
gies, Inc. The anti–mouse and anti–rabbit peroxidase-conjugated second-
ary antibodies as well as the FITC and Texas red–conjugated anti–mouse
and anti–rabbit antibodies were from Dakopatts.
Biochips screening
The laboratory-designed microarray containing 4,200 genes was previ-
ously described (Moreilhon et al., 2004). The list of probes spotted on the
microarray is available at http://medlab.ipmc.cnrs.fr/gene_List.html. To-
tal RNAs (10  g) were reverse transcribed using the CyScribe First-Strand
cDNA labeling kit (RPN 6200; Amersham Biosciences). Microarrays were
hybridized with the Cy3/Cy5 mixed sample overnight at 42 C, and were
washed at RT in 1  SSC/0.03% SDS for 5 min, in 0.2  SSC for 5 min,
and in 0.05  SSC for 5 min. Slides were scanned using a confocal scan-
ner (Scan Array 5000; GSI Lumonics). Images were analyzed by the
Quant Array software.
Quantitative real-time one-step RT-PCR and Western blot
RNAs were extracted using TRIzol reagent (Invitrogen) and Rneasy protect
mini kit (QIAGEN). mRNA expression levels were quantified by real-time
one-step RT-PCR using SYBR-Green PCR Master Mix (Applied Biosystems).
The results are the average of three separate experiments.
For the Western blot analysis, subconfluent cells were lysed in
Laemmli buffer. The protein concentration was determined using the Lowry
assay and 50  g total cell extracts was resolved by SDS-PAGE (7.5% for
HIF1  detection) and electrophoretically transferred onto a PVDF mem-
brane (Millipore). Immunoreactive bands were visualized using the ECL
system (Amersham Biosciences).
Chromatin immunoprecipitation assay
B16 cells were stimulated (or not) with forskolin for 5 h and were then
treated with 1% formaldehyde for 5 min at 37 C and for 30 min at 4 C.
Next, cells were harvested and suspended in the lysis buffer (10 mM
Hepes, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40, and pro-
tease inhibitors). After 10 min incubation on ice, cells were centrifuged
(5,000 rpm, 5 min at 4 C) to pellet the nuclei. Nuclei were then sus-
pended in the nuclei lysis buffer (50 mM Tris-Cl, pH 8.1, 10 mM EDTA,
1% SDS, and protease inhibitors) and incubated on ice for 10 min. The
sheared chromatin was then immunoprecipitated using (or not) a specific
polyclonal anti-MITF antibody (Bertolotto et al., 1998b). After immunopre-
cipitation, the cross-link was reverted by heat treatment (67 C overnight
and proteinase K digestion). The genomic captured fragments were then
recovered by phenol-chloroform extraction. Identification of the captured
Hif1a or tyrosinase promoter fragments was performed by PCR analysis
using the promoter primers. 30 cycles of PCR were performed and the am-
plified products were analyzed on a 2% agarose gel.
Transfections and luciferase assays
B16 melanoma cells and NIH-3T3 fibroblasts were seeded in 24-well
dishes, and transient transfections were performed the following day using
2  l Lipofectamine (GIBCO BRL) and 0.5  g total plasmid DNA or 20 nM
annealed siRNAs, in a 200- l final volume. pCMV Gal was cotransfected
with the test plasmids to control the variability of transfection efficiency in
the reporter assays. 24 h after transfection, soluble extracts were harvested
in 50  l of lysis buffer and assayed for luciferase and  -galactosidase ac-
tivities. All transfections were repeated several times using different plas-
mid preparations.
Immunofluorescence microscopy
siRNA-transfected B16 melanoma cells cultured on glass coverslips were
washed three times in PBS, fixed for 20 min in 3% PFA, washed again,
and incubated for 10 min in 50 mM NH4Cl. After three more washes,
cells were incubated with the primary antibody diluted in PBS containing
0.5% BSA and 0.02% saponin for 1 h, washed abundantly in PBS, and
incubated for another hour with the appropriate conjugated secondary an-
tibody. After washing, the coverslips were incubated with bisbenzidine
(0.5  g/ml) to stain the nuclei, they were mounted on glass slides, and
viewed with an Axiophot fluorescent microscope (Carl Zeiss MicroImag-
ing, Inc.), using a 40 /0.75 Plan Neofluar objective lens. To acquire the
images, a COHU (High performance CCD camera) and the Q-Fish (Leica)
informatic software was used.
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